Literature DB >> 8449077

The relationship between alveolar macrophage TNF, IL-1, and PGE2 release, alveolitis, and disease severity in sarcoidosis.

R J Pueringer1, D A Schwartz, C S Dayton, S R Gilbert, G W Hunninghake.   

Abstract

A mononuclear cell alveolitis, comprised in part of activated macrophages, is thought to precede granuloma formation and fibrosis in pulmonary sarcoidosis. Tumor necrosis factor-alpha (TNF), interleukin 1-beta (IL-1), and prostaglandin E2 (PGE2) are potent mediators released by activated alveolar macrophages. To determine if alveolar macrophage TNF, IL-1, and PGE2 release was associated with clinically progressive pulmonary sarcoidosis, we obtained alveolar macrophages from bronchoalveolar lavage of 68 patients with biopsy specimen-confirmed sarcoidosis, cultured the macrophages in the presence and absence of lipopolysaccharide (10 mg/L) for 24 h, and measured TNF (enzyme-linked immunosorbent assay), IL-1 (enzyme-linked immunosorbent assay), and PGE2 (radioimmunoassay) release. Alveolar macrophages from most patients with sarcoidosis spontaneously released TNF, IL-1, and PGE2. The amounts of these mediators released (either spontaneously or following lipopolysaccharide stimulation) did not positively correlate with the numbers of any of the cells in bronchoalveolar lavage fluid, the clinical status of disease (stable vs deterioration), steroid usage, or cigarette smoking. The relative release of each of the individual mediators, however, was highly correlated with the release of the other mediators. The studies suggest that these markers of alveolar macrophage activation from a single bronchoalveolar lavage are poor indicators of clinically progressive disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8449077     DOI: 10.1378/chest.103.3.832

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  12 in total

Review 1.  A clinical approach to the use of methotrexate for sarcoidosis.

Authors:  R P Baughman; E E Lower
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

2.  Shed soluble ICAM-1 molecules in bronchoalveolar lavage cell supernatants and serum of patients with pulmonary sarcoidosis.

Authors:  I Bäumer; G Zissel; M Schlaak; J Müller-Quernheim
Journal:  Lung       Date:  1997       Impact factor: 2.584

3.  Mathematical model of sarcoidosis.

Authors:  Wenrui Hao; Elliott D Crouser; Avner Friedman
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-27       Impact factor: 11.205

4.  Prostaglandin E₂ inhibits human lung fibroblast chemotaxis through disparate actions on different E-prostanoid receptors.

Authors:  Ying-Ji Li; Xing-Qi Wang; Tadashi Sato; Nobuhiro Kanaji; Masanori Nakanishi; Miok Kim; Joel Michalski; Amy J Nelson; Jian-Hong Sun; Maha Farid; Hesham Basma; Amol Patil; Myron L Toews; Xiangde Liu; Stephen I Rennard
Journal:  Am J Respir Cell Mol Biol       Date:  2010-03-04       Impact factor: 6.914

5.  Correlation of CD4:CD8 ratio and tumour necrosis factor (TNF)alpha levels in induced sputum with bronchoalveolar lavage fluid in pulmonary sarcoidosis.

Authors:  Y P Moodley; T Dorasamy; S Venketasamy; V Naicker; U G Lalloo
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

6.  Association between sarcoidosis and lymphoma revisited.

Authors:  M Karakantza; E Matutes; K MacLennan; N T O'Connor; P C Srivastava; D Catovsky
Journal:  J Clin Pathol       Date:  1996-03       Impact factor: 3.411

7.  Altered Cyclooxygenase-2 Expression in Pulmonary Sarcoidosis is not Related to Clinical Classifications.

Authors:  Justyna Kiszałkiewicz; Wojciech J Piotrowski; Dorota Pastuszak-Lewandoska; Paweł Górski; Adam Antczak; Witold Górski; Daria Domańska-Senderowska; Monika Migdalska-Sęk; Karolina H Czarnecka; Ewa Nawrot; Ewa Brzeziańska-Lasota
Journal:  Inflammation       Date:  2016-08       Impact factor: 4.092

8.  Disordered Toll-like receptor 2 responses in the pathogenesis of pulmonary sarcoidosis.

Authors:  M I Gabrilovich; J Walrath; J van Lunteren; D Nethery; M Seifu; J A Kern; C V Harding; L Tuscano; H Lee; S D Williams; W Mackay; J F Tomashefski; R F Silver
Journal:  Clin Exp Immunol       Date:  2013-09       Impact factor: 4.330

9.  Spontaneous interleukin 2 release of bronchoalveolar lavage cells in sarcoidosis is a codeterminator of prognosis.

Authors:  J Müller-Quernheim; S Pfeifer; K Kienast; G Zissel
Journal:  Lung       Date:  1996       Impact factor: 2.584

10.  Pulmonary Sarcoidosis Induced by Adalimumab: A Case Report and Literature Review.

Authors:  Jae Kyeom Sim; Sung Yong Lee; Jae Jeong Shim; Kyung Ho Kang
Journal:  Yonsei Med J       Date:  2016-01       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.